Michael Mesa

Has successfully managed the ATNAA auto-injector for the treatment of nerve agent poisoning, and anti-seizure auto-injectors such as the CANA and the AAS programs.

Developed a benzodiazepine auto-injector used in the NIH-sponsored RAMPART Study and the King Pharmaceuticals’ RESCUE Study.

Was a key figure in the development of the EpiPen® Auto-injectors and is a named inventor on multiple EpiPen U.S. and foreign patents and patent applications.